SCHEMBL21664079

SCHEMBL21664079

Cn1ccc(C2=NCCS2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
KEAP1 Q14145 1/20 0.39
KCNH2 Q12809 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
SCN4A P35499 1/20 0.33
PIK3CD O00329 1/20 0.33
PIP5K1C O60331 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PI4KA P42356 1/20 0.33
PIK3CG P48736 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
CYP19A1 P11511 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18157906 0.70 KMT2A (0.64) KMT2AKEAP1SMN1; SMN2LMNASCN4A
SCHEMBL28172501 0.60 KMT2A (0.52) KMT2AKEAP1SMN1; SMN2LMNASCN4A
SCHEMBL8378973 0.59 MGLL (0.43) KMT2ASMN1; SMN2LMNAALDH1A1MAPT
SCHEMBL26952025 0.59 KMT2A (0.55) KMT2AKEAP1SCN4APIK3CDPIP5K1C
SCHEMBL9385111 0.58 KMT2A (0.51) KMT2ASMN1; SMN2ALDH1A1MAPTPOLB
SCHEMBL26638821 0.58 KMT2A (0.44) KMT2AKEAP1SMN1; SMN2SCN4APIK3CD
SCHEMBL3471441 0.58 RAB9A (0.45) KMT2AKEAP1SMN1; SMN2LMNASCN4A
SCHEMBL17812984 0.57 KMT2A (0.54) KMT2AKEAP1SCN4ACYP19A1MAPT
SCHEMBL12319225 0.57 KEAP1 (0.67) KMT2AKEAP1SMN1; SMN2LMNASCN4A
SCHEMBL9788624 0.57 NPC1 (0.49) ALDH1A1MAPTNOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 KMT2A 4395/4885KEAP1 2844/4885KCNH2 1226/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 KMT2A 4395/4885KEAP1 2844/4885KCNH2 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.